Fate Therapeutics Announces Phase 1 Data Presentation of FT819 Off-the-Shelf CAR T-cell Product Candidate for SLE at EULAR 2025 Congress
SAN DIEGO, May 28, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived off-the-shelf cellular immunotherapies to patients, today announced that clinical and preclinical data from the Company's off-the-shelf cell therapy product platform will be featured at the European Alliance of Associations for Rheumatology European Congress of Rheumatology (EULAR 2025), being held in Barcelona, Spain on June 11-14, 2025.
The Company has been selected to provide an oral presentation featuring clinical data from its ongoing Phase 1 clinical trial of FT819, its off-the-shelf, CD19-targeted, 1XX CAR T-cell product candidate, in patients with moderate-to-severe systemic lupus erythematosus (SLE) (NCT06308978). The Phase 1 study is designed to evaluate the safety and activity of FT819 in patients receiving either a fludarabine (flu)-free conditioning regimen or maintenance therapy without conditioning. In addition, the Company will highlight preclinical and translational data from its off-the-shelf, iPSC-derived, CAR T-cell and CAR-NK cell product platform across multiple autoimmune indications, including the use of Sword and Shield technology and multi-antigen targeting to circumvent the need for conditioning chemotherapy, enhance therapeutic outcomes, and maximize patient access by enabling outpatient treatment.
Accepted abstracts are available on the EULAR 2025 website. Presentation details are as follows:
Oral Presentation
Treatment of Refractory Systemic Lupus Erythematosus with Off-the-Shelf iPSC-derived Anti-CD19 CAR T-cell Therapy
Session: Cell Therapies – CAR-T and BeyondPresentation Date / Time: Wednesday, June 11, 2025 / 3:20 PM CEST
Poster Presentations
Next-Generation Off-the-Shelf CAR T Cells: A Novel Platform to Enable Comprehensive Elimination of Aberrant Effector Cells for the Treatment of Autoimmune Diseases in the Absence of Conditioning Chemotherapy
Session: Basic and Clinical Poster Tours: CAR T-cells and other emerging Therapies Presentation Date / Time: Thursday, June 12, 2025 / 9:54am CEST
Next Generation CAR-NK cell Therapy Leverages Alloimmune Defense Technology to Persist Without Conditioning Chemotherapy for the Treatment of Autoimmune Disease
Session: Poster View VIIIPresentation Date / Time: Saturday, June 14, 2025 / 10:15-11:45am CEST
About Fate Therapeutics' iPSC Product PlatformHuman induced pluripotent stem cells (iPSCs) possess the unique dual properties of unlimited self-renewal and differentiation potential into all cell types of the body. The Company's proprietary iPSC product platform combines multiplexed-engineering of human iPSCs with single-cell selection to create clonal master iPSC lines. Analogous to master cell lines used to mass produce biopharmaceutical drug products such as monoclonal antibodies, the Company utilizes its clonal master iPSC lines as a starting cell source to manufacture engineered cell products which are well-defined and uniform in composition, can be stored in inventory for off-the-shelf availability, can be administered in combination with other therapies, and can potentially reach a broad patient population. As a result, the Company's platform is uniquely designed to overcome numerous limitations associated with patient- and donor-sourced cell therapies. Fate Therapeutics' iPSC product platform is supported by an intellectual property portfolio of over 500 issued patents and 500 pending patent applications.
About Fate Therapeutics, Inc.Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered master iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company's pipeline includes iPSC-derived T-cell and natural killer (NK) cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.
Forward-Looking StatementsThis release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 including statements regarding the advancement of and plans related to the Company's product candidates, clinical studies and preclinical research and development programs, the Company's progress, plans and timelines for the clinical investigation of its product candidates, the availability of data from the Company's clinical trials and the Company's plans to provide updates on its clinical trials, the therapeutic and market potential of the Company's research and development programs and product candidates, and the Company's clinical and product development strategy. These and any other forward-looking statements in this release are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that the Company's research and development programs and product candidates, including those product candidates in clinical investigation, may not demonstrate the requisite safety, efficacy, or other attributes to warrant further development or to achieve regulatory approval, the risk that results observed in prior studies of the Company's product candidates, including preclinical studies and clinical trials, will not be observed in ongoing or future studies involving these product candidates, the risk of a delay or difficulties in the manufacturing of the Company's product candidates or in the initiation and conduct of, or enrollment and continued participation of patients in, any clinical trials, the risk that the Company may cease or delay preclinical or clinical development of any of its product candidates for a variety of reasons (including requirements that may be imposed by regulatory authorities on the initiation or conduct of clinical trials, changes in the therapeutic, regulatory, or competitive landscape for which the Company's product candidates are being developed, the amount and type of data to be generated or otherwise to support regulatory approval, difficulties or delays in patient enrollment and continuation in the Company's ongoing and planned clinical trials, difficulties in manufacturing or supplying the Company's product candidates for clinical testing, failure to demonstrate that a product candidate has the requisite safety, efficacy, or other attributes to warrant further development, and any adverse events or other negative results that may be observed during preclinical or clinical development), and the risk that its product candidates may not produce therapeutic benefits or may cause other unanticipated adverse effects. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the Company's actual results to differ from those contained in the forward-looking statements, see the risks and uncertainties detailed in the Company's periodic filings with the Securities and Exchange Commission, including but not limited to the Company's most recently filed periodic report, and from time to time in the Company's press releases and other investor communications. Fate Therapeutics is providing the information in this release as of this date and does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.
Contact:Christina TartagliaPrecision AQ212.362.1200christina.tartaglia@precisionaq.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
18 minutes ago
- Associated Press
LINE LOSS ALERT: Lineage, Inc. Investors with Losses are Reminded of the September 30 Class Action Deadline – Contact BFA Law (NASDAQ:LINE)
NEW YORK, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Lineage, Inc. (NASDAQ: LINE) and certain of the Company's senior executives and directors for potential violations of the federal securities laws. If you invested in Lineage, you are encouraged to obtain additional information by visiting: Investors have until September 30, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 11 and 15 of the Securities Act of 1933 on behalf of investors who purchased stock pursuant and/or traceable to Lineage's registration statement for its initial public offering held on or about July 25, 2024. The case is pending in the U.S. District Court for the Eastern District of Michigan and is captioned City of St. Clair Shores Police and Fire Retirement System v. Lineage, Inc., et al., No. 2:25-cv-12383. Why Was Lineage Sued Under the Federal Securities Laws? Lineage is a cold storage focused real estate investment trust ('REIT'). Through its Global Warehousing Segment, Lineage owns and operates hundreds of temperature-controlled storage facilities used by companies to store food and other perishable products. As alleged, Lineage's IPO documents touted its 'consistent cold chain demand,' which purportedly provided Lineage 'with strong cash flows even during periods of broader economic stress.' The IPO documents also represented that the lingering effects of the COVID-19 pandemic had 'accelerated trends that . . . have the potential to be growth engines for the industry in coming years.' In truth, Lineage was allegedly in the midst of a sustained downturn, as its customers destocked excess inventory built up during the COVID-19 pandemic, and also shifted to leaner inventories on a go-forward basis and as more cold-storage supply came on line. Events Following the IPO On February 26, 2025, Lineage announced its fiscal Q4 2024 financial results, revealing that customers had been 'unwinding' previously 'overbuil[t]' levels of inventory, returning to a 'more normal seasonal pattern' that was expected to 'continue moving forward.' Lineage conducted its IPO at $78 per share. Since the IPO, the price of Lineage stock has fallen dramatically, to lows near $40 per share—approximately half the IPO price. Click here for more information: What Can You Do? If you invested in Lineage you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. Submit your information by visiting: Or contact: Ross Shikowitz [email protected] 212.789.3619 Why Bleichmar Fonti & Auld LLP? BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named 'Elite Trial Lawyers' by the National Law Journal, among the top '500 Leading Plaintiff Financial Lawyers' by Lawdragon, 'Titans of the Plaintiffs' Bar' by Law360 and 'SuperLawyers' by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.'s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd. For more information about BFA and its attorneys, please visit Attorney advertising. Past results do not guarantee future outcomes.
Associated Press
18 minutes ago
- Associated Press
RXST LOSS ALERT: RxSight, Inc. Investors with Losses are Reminded of the September 22 Class Action Deadline – Contact BFA Law (NASDAQ:RXST)
NEW YORK, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against RxSight, Inc. (NASDAQ: RXST) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in RxSight, you are encouraged to obtain additional information by visiting: Investors have until September 22, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased RxSight securities. The case is pending in the U.S. District Court for the Central District of California and is captioned Makaveev v. RxSight, Inc., et al., No. 25-cv- 01596. Why Was RxSight Sued for Securities Fraud? RxSight is engaged in the manufacture and sale of light adjustable intraocular lenses used in cataract surgery along with capital equipment used with the lenses. The Company's main product is its Light Adjustable Lens (LAL) that can be customized after cataract surgery through a series of non-invasive light treatments. These treatments, using a Light Delivery Device (LDD), adjust the lens's shape and power to optimize vision based on the patient's individual needs and preferences. During the relevant period, the Company touted its strong LAL and LDD sales and failed to disclose 'adoption challenges' in its products. In reality, RxSight was experiencing a slowdown in LAL utilization that was first noted in 2024. The Stock Declines as the Truth Is Revealed On April 3, 2025, before the market opened, RxSight cut its 2025 full-year revenue forecast citing a 'softening' of the market that purportedly occurred 'in the second half of 2024.' On this news, the price of RxSight stock declined roughly 38%, from $26.12 per share on April 2, 2025, to $16.21 per share on April 3, 2025. Then on July 8, 2025, the Company further cut its 2025 full-year revenue forecast. RxSight attributed the adjustment to 'the slower ramp in LAL utilization that was first noted in 2024' and '[a]doption challenges over the last few quarters.' On this news, the price of RxSight stock declined roughly 38%, from $12.79 per share on July 8, 2025, to $7.95 per share on July 9, 2025. Click here for more information: What Can You Do? If you invested in RxSight you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. Submit your information by visiting: Or contact: Ross Shikowitz [email protected] 212.789.3619 Why Bleichmar Fonti & Auld LLP? BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named 'Elite Trial Lawyers' by the National Law Journal, among the top '500 Leading Plaintiff Financial Lawyers' by Lawdragon, 'Titans of the Plaintiffs' Bar' by Law360 and 'SuperLawyers' by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.'s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd. For more information about BFA and its attorneys, please visit Attorney advertising. Past results do not guarantee future outcomes.
Yahoo
21 minutes ago
- Yahoo
After Gaining $394 Billion in Market Cap in 3 Days, Is Apple Stock on Its Way to Joining Nvidia and Microsoft in the $4 Trillion Club?
Key Points Apple's U.S. manufacturing investment could lower its tariff expense. The company's results are improving, but growth is still sluggish. Apple needs to justify its lofty valuation with AI-related product upgrades that are well-received by its diverse user base. 10 stocks we like better than Apple › After closing at $202.69 per share on Aug. 5, Apple (NASDAQ: AAPL) stock soared a staggering 13% in just three days to finish Aug. 8 at $229.09 per share. The move pole-vaulted the tech giant's market cap to $3.404 trillion -- a whopping $394 billion gain. That's like creating a company the size of Home Depot out of thin air. After languishing for most of the year, let's determine if Apple has what it takes to join Nvidia (NASDAQ: NVDA) and Microsoft (NASDAQ: MSFT) in the $4 trillion market cap club, and if the growth stock is a buy now. Apple's massive news Apple's sudden pop came in response to its $100 billion manufacturing program. Announced last week, the program will create American jobs and onshore some of Apple's complex supply chain. Due to Apple CEO Tim Cook's visit to the White House and Apple's manufacturing commitment, President Trump said that Apple would be 100% exempt from a specific tariff on imported semiconductors. The potential for Apple to reduce its costly tariff expense, and maybe even get government support for its onshoring efforts, is undoubtedly a boon for the company's near-term prospects. Apple isn't the only mega-cap company that is trying to work with the current administration on tariffs. On Monday, reports indicated that Nvidia made a deal with President Trump, allowing the chipmaker to resume exporting its H20 chips in exchange for giving the U.S. government 15% of its revenue from China. The H20 is a scaled-down version of Nvidia's most advanced chips, which are custom-built for Chinese markets to comply with trade restrictions. The current administration intends to retain certain tariffs, but it also appears willing to negotiate deals with big businesses. Apple's manufacturing news is positive, based on the near-term impact of tariffs. The investment could help Apple reduce its sensitivity to trade tensions and geopolitical risk. However, it's unclear how it impacts Apple's long-term investment thesis. Apple has mastered the art of managing a global supply chain to achieve cost advantages and boost its profit margins. Onshoring some of its supply chain could lead to higher costs. However, Apple has yet to make a meaningful splash in artificial intelligence (AI) -- which is one of the main reasons why the tech giant has been lagging behind the performance of other, more defined AI winners like Nvidia and Microsoft. In Apple's defense, the company has built on Apple Intelligence and released a new design update called Liquid Glass. Overall, the market is not impressed with the company's AI efforts, considering how sluggish Apple's growth has been in recent years. Apple's earnings growth doesn't justify its lofty valuation Apple has heavily relied on its high-margin services segment and stock buybacks to drive earnings to offset weak results from its product segment. Apple's services, which include iCloud, Apple Music, and Apple TV+, have been the standout for years now. But Apple's bottom line depends more on key products, like iPhone, Mac, iPad, and wearables. Investors breathed a sigh of relief after Apple's latest quarter -- the third quarter of fiscal 2025 -- which showed a significant improvement in its product segment. Revenue grew 10% and diluted earnings per share (EPS) jumped 12% including double-digit growth in iPhone, Mac, and services. Despite the solid quarter, Apple's net income has slightly declined over the last three years, so its earnings are only up due to buybacks. But the stock price has gone up substantially, which has made Apple relatively expensive. Apple's results are headed in the right direction, but the valuation is far from cheap. In fact, Apple's forward price-to-earnings (P/E) ratio, which is the stock price divided by analyst consensus EPS estimates over the next 12 months, is higher than its five-year and 10-year median P/E ratios. Even if Apple performs as expected and the stock price doesn't move for a year, it will still be relatively expensive. Apple has to earn $4 trillion the hard way Apple is taking the right approach to integrating AI across its product suite. Apple's competitive advantages are its design, user-friendly products, seamless integration of software and hardware, and comprehensive product offerings for consumers and businesses. In other words, the everyday usefulness of Apple's AI features is the most important performance indicator. Investors who agree with Apple's deliberate approach to AI may still want to consider buying the stock now, despite the premium valuation. However, given how pricey Apple is, its road to $4 trillion in market cap will likely need to come from earnings growth rather than valuation expansion. With a market cap of $3.418 trillion at the time of this writing, Apple would have to jump 17% to cross $4 trillion. It could certainly grow earnings by that much in a year or two. And if investors like what the company is doing with AI, it could maintain its higher-than-historical valuation. All told, I expect Apple to cross $4 trillion in market cap by the end of 2026 -- but investors shouldn't expect the company to get there overnight -- even after adding $392 billion in market cap in just three days. Should you invest $1,000 in Apple right now? Before you buy stock in Apple, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Apple wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $663,630!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,115,695!* Now, it's worth noting Stock Advisor's total average return is 1,071% — a market-crushing outperformance compared to 185% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Daniel Foelber has positions in Nvidia. The Motley Fool has positions in and recommends Apple, Home Depot, Microsoft, and Nvidia. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy. After Gaining $394 Billion in Market Cap in 3 Days, Is Apple Stock on Its Way to Joining Nvidia and Microsoft in the $4 Trillion Club? was originally published by The Motley Fool Sign in to access your portfolio
